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performed to test the role of neoadjuvant chemotherapy. Some of 
these trials showed contradictory results (esp. Kelsen-RTOG(3) versus 
Allum/Clark-MRC(4)), but the overall 5-year survival advantage with 
neoadjuvant chemotherapy is probably <5%.(5) In most RCTs 
comparing neoadjuvant chemoradiotherapy followed by surgery versus 
surgery alone no significant benefit for the combined modality arm 
could be demonstrated. However, most of these (older) trials did not 
meet today’s standard of care and were generally underpowered. In 
the meta-analysis a survival benefit was suggested with the use of 
preoperative chemoradiotherapy.(6) 
Recently, we published the results of a multicenter Dutch RCT, 
comparing chemoradiotherapy (5 courses of weekly paclitaxel/ 
carboplatin and concurrent radiotherapy, 23x 1.8 Gy) followed by 
surgery versus surgery alone.(7) In general, toxicity was mild. In-
hospital mortality was comparable (4% in both groups) and no 
difference in postoperative morbidity was observed. The R0-radical 
resection rate was higher in the multimodality arm (92% vs. 69%). 
Median overall survival was superior in the multimodality arm (49% vs 
24%), while 5-year overall survival was 47% in the multimodality arm 
versus 34% in the surgery alone arm (p=0.003). Therefore, we now 
consider neoadjuvant chemoradiotherapy plus radical surgical 
resection as standard treatment for patients with potentially curable 
(cT1b-N1M0, cT2-4aNxM0) esophageal cancer. 
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In this short lecture, recent progress in radiation therapy (RT) for 
locally advanced esophageal cancer in Japan will be presented.  At 
present, concurrent chemotherapy (CT) of 5-FU/cisplatin combined 
with RT is a standard chemo-radiotherapy (CRT) regimen for locally 
advanced esophageal cancer.  Although full dose 5-FU/cisplatin is 
combined with RT in the USA, several Japanese investigators showed 
promising clinical results using low dose protracted infusion CT 
combined with full dose RT of 60-66 Gy for locally advanced 
esophageal squamous cell carcinomas.  Low dose protracted infusion 
of 5-FU or 5-FU plus cisplatin were proposed to reduce the acute 
toxicities due to concurrent CRT.  In addition, to obtain maximum 
radio-sensitization by CT, daily administration of low dose protracted 
CT combined with RT may be better than full dose short-term CT plus 
RT.  To test the above hypothesis, a randomized phase II study was 
conducted to compare the relative toxicity and efficacy of combining 
full dose short-term CT (arm A) or low dose protracted CT (arm B) 
with RT for esophageal cancer (KROSG0101/JROSG021) (1).  As a final 
analysis, low dose protracted infusion CT with RT is not superior to 
full dose short-term infusion CT with RT for esophageal cancer.  For 
both groups, late toxicities of grade 3 or more were noted 17-18% of 
the patients.  Most of the toxicities were cardiac or pleural toxicities, 
and patients with severe late toxicities often had coexistent 
hypothyroidism.         
To determine the clinical results of CRTfor esophageal cancer in 
Japan, a questionnaire-based survey for esophageal cancer treated by 
definitive RT between 1999 and 2003 was conducted (2).  Clinical 
results of definitive RT for patients were collected from 9 major 
institutions.  Only patients with good performance status (PS0-2) who 
received a total dose of 50 Gy or more were included.  Patients were 
classified into three groups; A) stage I-B) resectable stages II-III-C) 
unresectable stages III-IVA.  For group A, all patients treated by RT 
alone or chemo-radiotherapy (CRT) were included.  For groups B and 
C, only those treated by CRT were included.  The median total RT 
dose ranged from 60 Gy to 66 Gy.  The median and range of the 5-year 
overall survival rates were 56% (48-83%) for group A,29% (12-52%) for 
group B, and 19% (0-31%) for group C, respectively.  A significant 
disparity in survival rates wa snoted among the institutions for stage 
II-IVA tumors treated by CRT.  Interestingly, a significant correlation 
between the number of patients treated per year and the 5-year 
overall survival rate was noted for groups B and C (both p<0.05).  A 
similar volume-outcome relation was demonstrated between the 
number of esophagectomy operations performed per year and the 
operative mortality (3).  Thus, treatment of esophageal cancer should 
be done in limited number of large cancer center hospitals. 
To reduce the late toxicities, improvement in spatial dose distribution 
for esophageal cancer was obtained by conformal RT including 
intensity modulated RT (IMRT).  IMRT is an ideal boost technique for 
locally advanced cervical and upper thoracic esophageal cancers to 
exclude the spinal cord.  We are planning a phase II trial for cervical 
esophageal cancer using IMRT.   
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Radiotherapy in combination with concurrent cisplatin based 
chemotherapy of patients with locally advanced esophageal cancer 
results in 5 year overall survival between 10-30%. In meta-analysis of 
randomized trials comparing surgical treatment with or without 
neoadjuvant chemoradiation to chemoradiation, overall survival was 
identical (Hazard ratio 0.98) for both treatment strategies (1). 
Chemoradiation was associated with a significantly higher locoregional 
recurrence rate (HR:1.54) and a borderline significant lower distant 
metastases rate (HR 0.72; 95%CL 0.52 – 1.01). Treatment related 
mortality was higher with surgical treatment (8.9% vs. 1.3%). The vast 
majority of patients in these trials had squamous cell cancer. The lack 
of a survival benefit for surgery in spite of improved locoregional 
tumor control is mainly a consequence of the relatively high 
treatment related mortality. In randomized trials comparing surgery 
to neodjuvant chemoradiation followed by surgery (2), an increased 
treatment related mortality was reported for patients with squamous 
cell carcinomas, but not for patients with adenocarcinomas. Whether 
this observation is simply the consequence of the less complicated 
surgery of typically distally located adenocarcinomas or is also due to 
lifestyle associated differences in weight and cardiopulmonary 
function, is not well understood. The clinical consequence is that 
patients with locally advanced adenocarcinomas should be treated 
with neoadjuvant treatment followed by surgery, whereas patients 
with squamous cell cancer patients have two options, neoadjuvant 
chemoradiation followed by surgery or primary chemoradiation. Since 
treatment related mortality is higher in patients with impaired 
cardiopulmonary function or poor performance status, primary 
chemoradiation is the preferred treatment, if these conditions are 
present. Tumor location above the carina seems also to be associated 
with a higher risk of perioperative mortality favouring chemoradiation 
for the majority of these patients. Treatment decision based on early 
response to neoadjuvant chemoradiation has also been propagated. 
Patients with responding tumors have a much better clinical outcome 
regardless of whether treatment is completed with surgery of further 
chemoradiation (3), and chemoradiation as the less toxic treatment is 
propagated in case of response. Independent of these considerations, 
new treatment strategies are needed to improve clinical outcome. 
Chemoradiation with total doses between 50 to 65 Gy in combination 
with cisplatin based chemotherapy is standard at the time. The 
addition of taxanes and cetuximab is currently under investigation. 
Improved radiation technology like IMRT and IGRT are also under 
investigation and are expected to lower treatment related toxicity. 
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ICRU 50 and ICRU 62 documents established recommendations and 
procedures for the practice of Two-Dimensional Radiation Therapy 
(2D-RT) and to a lesser extent, Three-Dimensional Conformal 
Radiation Therapy (3D-CRT). Some of these recommendations were 
however only concepts, which, although extremely valid, were 
impractical to implement in modern radiotherapy.  In addition, new 
concepts to account for the practice of Intensity-Modulated Radiation 
Therapy (IMRT) were required. In this framework, ICRU 83 provides 
updates to the earlier documents to take into account changes in 
practice with IMRT and evolving improved practice in 3D-CRT. 
IMRT and 3D-CRT required the use of accurate guidelines for the 
selection and delineation of the various target volumes on a 
volumetric basis. In addition, various imaging modalities (including 
molecular imaging) may be used for planning not only before the start 
of treatment, but also during treatment to adapt the dose 
distribution.The concepts of gross tumor volume (GTV) and clinical 
target volume (CTV) have been crucial conceptually, but 
recommendations for outlining were needed for a practical 
implementation on a daily basis. Refinement for OAR delineation 
(e.g."tube" organs, "parallel-like or serial-like) were also provided. 
The IMRT planning process uses an optimizer, which expresses the 
radiation oncologist’s treatment goals.  The committee has designated 
the set of optimizer parameters the “planning aims” to differentiate 
from the usual meaning of “prescription”. Multiple recent publications 
have pointed out that the choice for planning target volume (PTV) 
margin should be based on clinical QA measurements and should place 
more emphasis on systematic uncertainties as they have more impact 
on the accuracy of dose delivered to the patient as compared to 
random uncertainties. Unlike 3D-CRT, IMRT does not deliver dose to 
all of the target volume a tone time.  IMRT delivered to moving organs 
may allow hot and cold spots to develop in the CTV even though a 
generous PTV margin has been drawn. IMRT has gained prominence 
because it allows a lower dose to neighboring sensitive normal tissues 
even though it may result in less dose homogeneity to the tumor.  
Therefore, the use of a single reference point for prescription and 
reporting recommended in earlier protocols can lead to unnecessary 
dose uncertainty and so the committee  recommended dose-volume 
reporting, for example, the dose which covers some high fraction of 
the target volume as preferable. Last, the implementation of IMRT 
requires adequate quality control of the equipment as well as of any 
individual plan to ensure proper dose delivery in accordance with the 
presciption. 
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The new joint ICRU/GEC ESTRO report (88, 2013) reflects and further 
structures the on-going developments in the field of IGABT and was 
preceded by 4 GEC ESTRO recommendations on adaptive target 
concepts, dose volume parameters, biological modelling, applicator 
reconstruction and imaging. They have become widely accepted in the 
international community and have become the basis of this report.  
The current report focuses on the volumetric image guided adaptive 
approach. It also includes traditional 2D planning which is linked to 
the 3D world by recommending point A.  
The GTV and CTV concepts follow the ICRU tradition with a special 
focus on the change of CTV during treatment. The High Risk CTV is 
introduced which represents residual GTV and surrounding are 
assumed to carry a high risk for residual cancer cells after 40-45 Gy 
EBRT plus chemotherapy and always the whole cervix. An additional 
Intermediate Risk CTV is suggested representing the area of tumour 
spread at diagnosis and a margin around the CTVHR. Uncertainties for 
GTV/CTV selection and contouring are recognized as due to internal 
motion and applicator reconstruction and discussed in the frame of 
intracavitary brachytherapy. The addition of margins (as in EBRT) is 
discouraged (dose escalation).  PTV has to be designed when planning 
the application which has to be adapted as appropriate.  
For adjacent OARs rectum, bladder and sigmoid 2cm³ and 0.1 cm³ are 
defined as reference. For the vagina anatomical reference points are 
recommended due to contouring and dosimetric uncertainties. 
Uncertainties due to internal motion are recognized for OARs and 
corrected through repetitive imaging. 
Dose (rate) per fraction is recommended to be reported as physical 
dose and calculated and reported as iso-effective dose in EQD2 
following the LQ model. Its pragmatic use is encouraged for treatment 
planning withan α/β value of 10 Gy for tumour and 3 Gy for OAR 
although its limitations are recognized. 
For the target the main dose volume parameter is D90, complemented 
by D98 as near-minimum dose and D50 indicating the high dose 
volume. Dose variation is around 200%.  
Point A is encouraged to be continued for dose reporting, clearly 
defined based on the applicator geometry. It will allow reproducible 
dose assessment for the 2D approach, but also consistency and 
comparability for the 3D approach. The TRAK remains an essential 
reporting parameter.  
For normal tissues D2cm³ and D0.1cm³ are the main parameters for 
the 3D approach. Additional  parameters for the mid and low dose 
region arediscussed, mainly reflecting EBRT. Applicator related points 
are recommended for the upper vagina (at 0/5 mm (ABS)) and 
anatomy related points for the mid and low vagina. For the 2D 
approach the dose points for rectum and bladder remain as defined in 
ICRU 38.  
The report also contains recommendations and information on 
treatment planning, applicator reconstruction, 3D dose summation, 
source strength specification and dose calculation.  
“Planning aim” (ICRU 83) is also introduced for brachytherapy 
treatment planning and represents a certain “treatment schedule” for 
a specific clinical scenario including a set of dose and volume 
parameters fora specific applicator. During the treatment planning 
optimization, adaptations are performed according to dose volume 
constraints for the target and OARs. “Prescription” is based on the 
final set of parameters which presents the treatment plan finally used 
for irradiation.  
The upcoming report is based on concepts and terms developed within 
the frame of the on-going technical and clinical developments. The 
terms support the transition from 2D to 3D/4D gynaecologic 
brachytherapy and have become integrated into the educational 
programmes of leading international Societies. They are being 
clinically validated in a spreading number of centres in Europe and 
worldwide. Research validation is on-going within various multi-centre 
trials (e.g. EMBRACE) which will help to define the”true” clinical 
value, reliability and reproducibility. These evaluations may require 
further adaptations.   
   
 
 
 
 
 
 
 
 
 
